NBIX technical analysis

NBIX Technical Analysis

Analysis date

July 17, 2026

Market

NasdaqGS (USD)

Daily cutoff

July 16, 2026

Reliability

Passed

Informational use only. This page is not investment advice.

Data verification

NBIX Data Verification

Cross-validating the latest completed daily bar across independent sources.

Symbol
NBIX
Market
NasdaqGS
Currency
USD (US Dollar)
Latest completed bar
July 16, 2026

No adjustment factor (adjusted close equals raw close, factor 1.0). No stock splits or dividend adjustments affecting the analysis period.

SourceLatest CloseDateDifferenceStatus
Yahoo Finance Chart API (primary)155.42July 16, 2026-Verified
Finviz (independent)155.42July 16, 2026 (previous close)0.00%Verified

Bottom line

NBIX Technical Analysis Summary

NBIX (Neurocrine Biosciences) displays a mixed technical picture with a bullish long-term trend but near-term overextension signals. On the daily chart, price at 155.42 sits above SMA20 (149.66) and SMA50 (145.31) but the bullish alignment is less pronounced than on the weekly timeframe. RSI14 at 66.82 is approaching overbought territory (above 70), suggesting caution on the daily timeframe. The MACD remains positive with the MACD line at 3.84 above the signal line at 3.02 with a histogram of 0.82, reflecting ongoing but moderating bullish momentum. The weekly timeframe shows a stronger structural uptrend with price at 152.68 above SMA20 (138.50), SMA50 (131.22), and SMA200 (112.55), with the SMA200 sloping upward. Weekly RSI at 60.85 is in healthy bullish territory without overextension. Key support lies at SMA20 (149.66) and the 20-day low (143.52). Major resistance is at the 52-week high of 175.40 and the 20-period high of 163.45. The stock is supported by a strong commercial franchise in Ingrezza and a promising late-stage pipeline in neurology, but the daily RSI approaching overbought levels warrants attention.

Multi-timeframe dashboard

Multi-Timeframe Technical Dashboard

Comparing daily (2-year) and weekly (5-year) perspectives to identify aligned or conflicting signals.

Daily (July 16, 2026)

Trend
Moderately bullish. Price at 155.42 is above SMA20 (149.66, +3.85%), SMA50 (145.31, +6.96%), and SMA200 (130.88, +18.75%). The SMA20 is above SMA50 which is above SMA200, maintaining a bullish alignment. However, the distance above SMA20 is relatively narrow, suggesting the near-term trend is less robust than the long-term trend. The SMA200 slopes upward, confirming structural support.
Momentum
Momentum is bullish but approaching caution levels. RSI14 at 66.82 is above the 50 midline and trending higher, nearing the 70 overbought threshold that has historically preceded short-term pullbacks. MACD line at 3.84 remains above the signal line at 3.02 with a positive histogram of 0.82, though the histogram has flattened over recent bars, suggesting momentum may be peaking.
Volatility
Moderate. ATR14 at 4.82 (3.10% of price) reflects manageable daily swings for a mid-cap biotech. Bollinger Bands (141.11 to 163.45) show a moderate width with price near the upper band, consistent with the current uptrend. The bands are not unusually wide, indicating orderly rather than volatile price action.
Volume
Below average. Latest volume of 1,048,700 is 72.3% of the 20-period average (1,451,200), suggesting reduced participation during the recent advance. This volume divergence relative to price action warrants attention, as low-volume rallies can lack conviction.

Assessment

The daily chart shows a stock in a moderately bullish trend with price above all key SMAs. However, RSI at 66.82 approaching overbought territory, a flattening MACD histogram, and below-average volume on the advance suggest the near-term momentum may be losing steam. The stock could experience a consolidation or pullback in the coming sessions. The primary risk is a mean-reversion move toward SMA20 support at 149.66. The bullish case rests on the structural uptrend remaining intact as long as price holds above SMA50 at 145.31.

Weekly (July 13, 2026 week)

Trend
Bullish. Price at 152.68 is above SMA20 (138.50, +10.24%), SMA50 (131.22, +16.34%), and SMA200 (112.55, +35.65%). All SMAs are in bullish alignment with positive slopes, confirming a sustained structural uptrend. The SMA200 at 112.55 highlights the magnitude of appreciation over the multi-year period.
Momentum
Bullish. RSI14 at 60.85 is in healthy bullish territory above the 50 midline, with no signs of bearish divergence. MACD line at 5.88 is above the signal line at 4.42 with a positive histogram of 1.46, confirming steady weekly momentum. The weekly momentum profile is more constructive than the daily, suggesting the primary trend remains upward.
Volatility
Moderate. ATR14 at 9.56 (6.26% of price) reflects normal weekly volatility for a mid-cap biotech. Bollinger Bands (120.48 to 168.76) show reasonable width, with price in the upper half of the range.
Volume
Near average. Weekly volume of 6,842,500 is 94.8% of the 20-week average (7,215,300), indicating steady participation without signs of exhaustion or accumulation.

Assessment

The weekly chart confirms a solid structural uptrend with price well above all key SMAs and the SMA200 sloping strongly upward. RSI at 60.85 provides room for further upside without being overbought. The positive MACD histogram confirms steady momentum. The 52-week position at 58.02% reflects a stock that has appreciated but still has room within its yearly range. The weekly framework supports the primary bullish view, though the daily chart suggests near-term caution.

Key indicators

NBIX Key Technical Indicators

RSI, MACD, moving averages, ATR, and Bollinger Bands across daily and weekly timeframes.

IndicatorDailyWeekly
RSI (14)66.8260.85
MACD (12, 26, 9)3.84 / 3.02 / 0.825.88 / 4.42 / 1.46
ATR (14)4.82 (3.10%)9.56 (6.26%)
Bollinger Bands (20, 2)141.11 - 163.45120.48 - 168.76
SMA (20)149.66138.50
SMA (50)145.31131.22
SMA (200)130.88112.55

Price structure

NBIX Price Structure and Returns

Price performance across multiple lookback periods and 52-week position.

MetricDailyWeekly
Current Price155.42152.68
1-Period Return+1.28%+2.15%
5-Period Return+3.41%+4.87%
20-Period Return+6.92%+11.43%
60-Period Return+14.28%+22.59%
252-Period Return+32.15%+42.78%
52-Week Low112.40112.40
52-Week High175.40175.40
52-Week Position59.18%58.02%

Key levels

NBIX Support and Resistance Levels

Key price levels based on recent swing highs and lows across daily and weekly timeframes.

LevelDailyWeekly
20-Period High163.45163.45
20-Period Low143.52127.65
60-Period High175.40175.40
60-Period Low134.18112.40

Scenarios

NBIX Technical Scenarios

Conditions, invalidation triggers, and what to watch for each scenario.

Bullish

Trigger

Price holds above SMA20 (149.66) and breaks above the 20-period high at 163.45 with above-average volume, targeting the 52-week high at 175.40.

Invalidation

Price closes below SMA50 (145.31) on a weekly basis, breaking the intermediate-term moving average structure.

What to watch

Daily RSI holding above 60; MACD histogram resuming expansion; volume confirming breakouts; Ingrezza prescription trends and Crinecerfont regulatory progress; quarterly earnings results and pipeline updates.

Consolidation

Trigger

Price oscillates between SMA20 support (149.66) and the 20-period high (163.45) as the stock digests recent gains, with RSI pulling back toward 55-60.

Invalidation

A decisive break above 163.45 or below 143.52 (20-day low) with increasing volume.

What to watch

RSI staying between 50 and 65; MACD histogram fluctuating near current levels; volume declining during the consolidation; sector sentiment toward biotech and neurology-focused companies.

Bearish

Trigger

Price breaks below the 20-day low at 143.52 and fails to hold SMA50 (145.31), suggesting a correction within the otherwise intact uptrend.

Invalidation

Price reclaims SMA20 (149.66) and establishes a higher low above 143.52.

What to watch

Daily RSI falling below 50; MACD line crossing below the signal line; volume increasing on down days; regulatory setbacks for pipeline candidates; Ingrezza competition from generics or alternative therapies.

Methodology

Methodology and Limitations

This technical analysis uses adjusted closing prices from Yahoo Finance (primary) and Finviz (independent cross-validation). The daily analysis covers approximately 2 years (502 completed bars) ending July 16, 2026. The weekly analysis covers approximately 5 years (261 completed bars) ending the week of July 13, 2026. Prices are adjusted for dividends and stock splits using the adjusted close/raw close ratio. Volume data is from the primary source and may not match other data providers. Technical indicators include SMA, RSI, MACD, ATR, and Bollinger Bands using standard parameters. Key levels are identified from recent swing highs and lows. Technical analysis studies historical price patterns and does not constitute investment advice. It should not be used as the sole basis for trading decisions.

Frequently Asked Questions

This technical analysis is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance and historical patterns are not guarantees of future results. All investments carry risk, including the potential loss of principal. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data sourced from Yahoo Finance (primary) and Finviz (independent cross-validation). Data cutoffs: daily July 16, 2026, weekly July 13, 2026 week. Generated July 17, 2026.